Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
This infographic provides industry professionals and senior scientists with insights into detailed methodologies for addressing stability challenges in protein therapeutics.
Aralez Bio, a San Francisco-based start-up, has engineered a platform of enzymes that creates 100 times more compound diversity using processes that are also 50 times greener than conventional methods.
US biotechnology company Neomorph signed a $1.46 billion licensing agreement with Novo Nordisk to discover, develop and commercialize molecular glue degraders.
Quotient Sciences, a drug development and manufacturing accelerator, has invested significantly in expanding its sterile fill/finish capabilities at its Alnwick, UK facility. This expansion aims to meet the rising demand in the industry for comprehensive drug development programs by enhancing the capacity of the Annex 1-compliant facility.
Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where Daiichi Sankyo retains exclusive rights. Merck to pay Daiichi Sankyo up to €20.8 billion for the collaboration.
Many life science companies generate large swathes of data.
US biopharma PTC Therapeutics has entered into a financing collaboration with private equity group Blackstone so that it can achieve its goal of delivering at least one therapy every two-to-three years.
Interview with Joachim Haupt and Florian Kaiser, PharmAI
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.
BASF has created ZoomLab, a virtual formulation prediction and optimization tool, to help address the challenges of drug product development.
Under the name M Lab, Germany’s Merck has opened a new collaborative drug development center in Pudong, Shanghai, China. The facility with lab space of around 10,000 m2 is the largest of the pharmaceutical, chemicals and life science group’s nine such centers worldwide and is located in the heart of Shanghai’s biomedical sciences and research community.
In 2019, the pharmaceutical industry invested $182 billion in drug development, but only 48 drugs were approved for use.
New therapies to address unmet and emerging medical needs are being discovered at an explosive rate, building on rapid advances in molecular biology and genetics.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
